Association Of The Class â…  Beta-Tubulin Gene Mutation And Drug Resistance Of The Treatment With Docetaxel For Advanced Non-Small Cell Lung Cancer

Lung cancer is one of the most popular malignant tumors and has the highest fatality rate of the malignant tumors. According to the histological classification,80%of the lung cancer is non-small cell lung cancer (NSCLC). Lacking of the effective early diagnosis, most of the newly diagnosed patients don’t have the chance to be operated. So chemotherapy is the main treatment for NSCLC. Docetaxel as the third generation cytotoxic drugs is used in first-line chemotherapy for advanced NSCLC. Likely the other chemotherapy, the docetaxel clinical application and chemotherapy effectiveness is influenced by the drug resistance which appeared constantly. It is of significance to clarify the mechanism of the docetaxel drug resistance, not only for the choice of treatment strategy, but also for improvement of chemotherapy effectiveness and to avoid the generation of the drug resistance in most even reverse it.Docetaxel is one of the chemotherapy drug class taxane, and it is a semi-synthetic analogue of paclitaxel, it can arrest cell mitosis by binding on microtubules, enhancing the stability of microtubules, and resulting in apoptosis at last. β-tubulin is the binding site that docetaxel combine with microtubules. So the changes of the β-tubulin are important to curative effect and drug resistance with docetaxel. The class Ⅰ β-tubulin is the most commonly expressed isotype in human beings and the most common isotype in cancer cells. Controversy persists in the existence of influence between β-tubulin gene mutation and docetaxel drug resistance. Here we will discuss the correlation of them, and provide foundation for the research of docetaxel drug resistance.We collected the information about TUBB(tubulin, beta class Ⅰ) that it encodes class Ⅰ p-tubulin from the National Center for Biotechnology Information(NCBI). The primers designed by Primer Premier5.0software were tested with the BLAST software on-line for the specificity. The regions of the fourth exon in TUBB from the advanced NSCLC patients were amplified with polymerase chain reaction (PCR), then whether point mutation existed were checked with nucleotide sequencing. According to curative effect association between point mutation and the treatment with docetaxel for NSCLC was analyzed.